Grace Kennedy, DO
Pulmonary Disease · Tulsa, OKNPI 1568478071
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (45.3%), food and beverage and consulting fees — rather than concentrated in one kind of arrangement. 42 manufacturers reported payments, led by Mylan Specialty L.p. at 49.8% of the total. Among pulmonary disease clinicians in OK with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 841 payments — averaging $67.30 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Mylan Specialty L.p.$28K
- Intuitive Surgical$7K
- Viatris Specialty LLC$4K
- Sanofi$4K
- AstraZeneca$3K
- Boehringer Ingelheim$2K
- plus $7K from 36 others
What the payments were for
- Consulting fees$7,68114%
- Speaking & faculty fees$25,61045%
- Travel & lodging$4,0937%
- Food & beverage$16,03728%
- Education$3,1746%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Yupelri$30,421
- Da Vinci Surgical System$4,041
- DUPIXENT$3,333
- DAVINCI XI$3,000
- OFEV$961
- FASENRA$744
- BEVESPI AEROSPHERE$500
- AIRSUPRA$383
- TEZSPIRE$267
- BREZTRI AEROSPHERE$249
- iTIND System$152
- SYMBICORT$132
- REMODULIN$114
- TYVASO$114
- NONE$114
- DRESSINGS$107
- BREZTRI$105
- NUCALA$101
How this compares
$56,595 in reported general payments places this provider in the 95th percentile of 133 pulmonary disease providers in Oklahoma.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OfevNintedanib Esylate | 102 | $1,438,507 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 803 | $756,881 |
| Dupixent PenDupilumab | 96 | $435,732 |
| OpsumitMacitentan | 33 | $424,620 |
| Tyvaso DpiTreprostinil | 16 | $374,970 |
| Prolastin CAlpha-1-Proteinase Inhibitor | 11 | $185,537 |
| NucalaMepolizumab | 44 | $180,500 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 183 | $154,292 |
| Spiriva RespimatTiotropium Bromide | 82 | $65,666 |
| Breo ElliptaFluticasone/Vilanterol | 91 | $53,453 |
| Gammagard LiquidImmun Glob G(Igg)/Gly/Iga Ov50 | 11 | $50,924 |
| Pirfenidone | 30 | $45,997 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 43 | $35,951 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 36 | $31,575 |
| Arnuity ElliptaFluticasone Furoate | 81 | $23,601 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimOfev, Spiriva Respimat, Stiolto Respimat, Combivent Respimat | $2,239 | $1,543,706231 claims |
| GSKTrelegy Ellipta, Nucala, Breo Ellipta, Anoro Ellipta, Arnuity Ellipta | $1,958 | $1,062,3571,078 claims |
| Actelion Pharmaceuticals US, Inc.Opsumit | $605 | $424,62033 claims |
| Grifols USA, LLCProlastin C | $331 | $185,53711 claims |
| AstraZenecaBreztri Aerosphere, Symbicort | $3,337 | $165,685217 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Gammagard Liquid | $186 | $50,92411 claims |
| MerckDulera | $200 | $11,20628 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 133 pulmonary disease providers in Oklahoma.
Other pulmonary disease in Tulsa
- Jennifer BierachTulsa$141K
- Hassan AbouhouliTulsa$103K
- Walter BoomerTulsa$43K
- Emil SchelbarTulsa$20K
- Andrew GottehrerTulsa$16K
- Bradley EdgingtonTulsa$12K
- Habiba HussainTulsa$10K
- Conner MoslanderTulsa$9K
- Pratyaksha SankhyanTulsa$9K
- Priyanka PathaniaTulsa$9K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.